Infections and antimicrobial prescribing in patients hospitalized with coronavirus disease 2019 (COVID-19) during the first pandemic wave.
Lynn ChanSimran GuptaAlicia J SaccoSabirah N KasuleHally ChaffinFionna F FellerLanyu MiElisabeth S LimMaria Teresa SevillePublished in: Antimicrobial stewardship & healthcare epidemiology : ASHE (2023)
Coinfection and secondary infections are common in patients who are critically ill with COVID-19 at hospital admission. Clinicians should consider starting antimicrobial therapy in critically ill patients while limiting antimicrobial use in patients who are not critically ill.
Keyphrases
- coronavirus disease
- sars cov
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- staphylococcus aureus
- primary care
- healthcare
- respiratory syndrome coronavirus
- stem cells
- prognostic factors
- mesenchymal stem cells
- patient reported outcomes
- bone marrow
- cell therapy
- patient reported
- adverse drug
- replacement therapy